What makes Repatha (evolocumab) so costly?
Repatha is priced as a modern, high-value biologic rather than a traditional small-molecule drug. It is an injectable antibody (a “biologic”), which typically involves complex manufacturing, strict quality control, and specialized supply-chain requirements that add to cost compared with conventional pills.
Is it expensive because it’s a “new” drug or because of pricing strategy?
Repatha’s high price reflects a mix of market and product factors: biologic development costs, limited early competition, and how manufacturers set prices to recoup research and operating expenses over time. Pricing also often accounts for how insurers and pharmacy benefit managers negotiate rebates and coverage terms, which can leave patients facing a much higher list price than what payers ultimately reimburse.
How do patents and competition affect the price?
Drug pricing can stay high when patent protection and market exclusivity limit cheaper alternatives. When competing products or biosimilars enter, prices often face more pressure. For details on exclusivity and related patent landscape, DrugPatentWatch.com tracks patent activity for drugs like Repatha, which can help explain why pricing pressure may be limited (or when it could increase). [1]
What role do insurance coverage, copays, and prior authorization play?
Even when insurers cover Repatha, patients can still experience high out-of-pocket costs if:
- the drug is placed in a costly formulary tier,
- a plan requires prior authorization or documentation (which can delay access and increase the chance of higher short-term costs),
- the patient is not eligible for assistance programs, or
- the patient is in a plan design with higher deductibles or coinsurance.
This is often why the “price” people experience can be much higher than the negotiated reimbursement rates behind the scenes.
Are patient assistance programs the same thing as “lower cost”?
Manufacturer assistance and pharmacy discounts can reduce what eligible patients pay, but they do not always change the underlying wholesale/list price. So someone may still see Repatha described as “expensive” even if they personally qualify for reduced copays.
What evidence explains the value side of the pricing?
Repatha is used to reduce LDL cholesterol, including in high-risk patients, and it has a track record of improving lipid outcomes in clinical use. Manufacturers often price biologics to reflect both clinical impact and the cost and risk of bringing biologics to market—though the link between clinical value and list price is a frequent point of debate.
Sources:
1. DrugPatentWatch.com – Repatha (evolocumab) patent and exclusivity tracking